EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 151 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,777 | -19.4% | 112,666 | -0.7% | 0.65% | -6.4% |
| Q2 2023 | $2,205 | -31.7% | 113,437 | -0.3% | 0.70% | -28.7% |
| Q1 2023 | $3,227 | -3.8% | 113,737 | -0.9% | 0.98% | -5.5% |
| Q4 2022 | $3,356 | -99.9% | 114,825 | -5.2% | 1.04% | +1.8% |
| Q3 2022 | $3,199,000 | -40.5% | 121,083 | +0.1% | 1.02% | -42.7% |
| Q2 2022 | $5,377,000 | -5.4% | 121,014 | +5.4% | 1.78% | -9.2% |
| Q1 2022 | $5,681,000 | +4.8% | 114,787 | +7.8% | 1.96% | +4.1% |
| Q4 2021 | $5,422,000 | -9.8% | 106,487 | -1.2% | 1.88% | -0.3% |
| Q3 2021 | $6,012,000 | +98.4% | 107,773 | +52.2% | 1.89% | +83.3% |
| Q2 2021 | $3,030,000 | – | 70,804 | – | 1.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |